menu
Intellia Therapeutics Head office building

Press Releases

Intellia Therapeutics Reports Financial Results for Third Quarter 2016

First company to report high in vivo editing data using CRISPR/Cas9 in animal models Further validation of lipid nanoparticle delivery platform Ended quarter with $290.6 million in cash and cash equivalents CAMBRIDGE, Mass. , Nov. 01, 2016 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc.
Read More

Intellia Therapeutics to Present at November Investor Healthcare Conferences

CAMBRIDGE, Mass. , Oct. 31, 2016 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on the development of potentially curative therapeutics using CRISPR/Cas9 technology, announced that senior company leaders will present at key November investor
Read More

Intellia Therapeutics to Present Data at the European Society of Gene & Cell Therapy Congress

CAMBRIDGE, Mass. , Oct. 14, 2016 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on the development of potentially curative therapeutics using CRISPR/Cas9 technology, announced that members of its scientific team will present new data at the
Read More

Intellia Therapeutics to Present at Jefferies Gene Editing/Therapy Summit

CAMBRIDGE, Mass. , Oct. 05, 2016 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on the development of potentially curative therapeutics using CRISPR/Cas9 technology, announced that Chief Medical Officer John Leonard , M.D., will participate
Read More

Intellia Therapeutics to Present at September Investor Healthcare Conferences

CAMBRIDGE, Mass. , Sept. 01, 2016 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on the development of potentially curative therapeutics using CRISPR/Cas9 technology, announced that CEO and Founder Nessan Bermingham , Ph.D., will present at
Read More

Intellia Therapeutics’ Preclinical Data Show Continued Progress in In Vivo Gene Editing With Systemic Lipid Nanoparticle Delivery of CRISPR/Cas9 components

CAMBRIDGE, Mass. , Aug. 18, 2016 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on the development of potentially curative therapeutics using CRISPR/Cas9 technology, presented preclinical data demonstrating in vivo gene editing using lipid
Read More

Intellia Therapeutics to Present at 2016 Wedbush PacGrow Healthcare Conference

CAMBRIDGE, Mass. , Aug. 10, 2016 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on the development of potentially curative therapeutics using CRISPR/Cas9 technology, announced that CEO and Founder Nessan Bermingham , Ph.D., will present at
Read More

Intellia Therapeutics Reports Financial Results for Second Quarter 2016

Advancing proprietary and partnered pipeline candidates with Novartis and Regeneron Cash and cash equivalents of approximately $300.7 million to accelerate CRISPR/Cas9 platform and pipeline development  CAMBRIDGE, Mass. , Aug. 04, 2016 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc.
Read More

Intellia Therapeutics to Present at the Jefferies 2016 Healthcare Conference and the International BIO Convention

CAMBRIDGE, Mass. , June 03, 2016 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading gene editing company focused on the development of potentially curative therapeutics using CRISPR/Cas9 technology, will present at both the upcoming Jefferies 2016 Healthcare Conference and the
Read More

Intellia Therapeutics Announces Closing of Initial Public Offering

Underwriters Exercise Over-Allotment Option CAMBRIDGE, Mass. , May 11, 2016 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA) today announced the closing of its initial public offering of 6,900,000 shares of its common stock at an initial public offering price of $18.00 per share, which
Read More
RSS FEEDS
PRINT PAGE